Depression in patients with Parkinson's disease

Parkinson's disease (PD) is a disabling neurodegenerative condition commonly complicated by the existence of comorbid depression. The prevalence rates of depression in this patient group have been reported to be as high as 40%. Currently, depression in PD is undertreated; there have been few controlled clinical trials of antidepressants in this patient group. Patients with PD are usually elderly and often administered a range of medication, therefore the choice of antidepressant must be undertaken with care. Tricyclic antidepressants (TCAs) have been studied in patients with PD and comorbid depression; however, the risk of anticholinergic side‐effects means that their use is largely avoided. Selective serotonin reuptake inhibitors have comparable efficacy to the TCAs and a better tolerability profile in patients with depression; they are rapidly being considered as first‐line therapy for PD patients with depression. Clinical studies in this patient group are warranted. This article reviews the characteristics of comorbid depression in patients with PD and discusses the treatment options available. Copyright © 1999 John Wiley & Sons, Ltd.

[1]  L. Cunningham.  Depression in the medically ill: choosing an antidepressant. , 1994, The Journal of clinical psychiatry.

[2]  E. Richelson,et al.  Pharmacokinetic interactions of antidepressants. , 1998, The Journal of clinical psychiatry.

[3]  C D Marsden,et al.  Depression in Parkinson's disease: a quantitative and qualitative analysis. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[4]  G. Dunbar.  Paroxetine in the elderly: a comparative meta-analysis against standard antidepressant pharmacotherapy. , 1995, Pharmacology.

[5]  R G Robinson,et al.  Depression in Parkinson's Disease , 1990, The Journal of nervous and mental disease.

[6]  P. Willner.  The mesolimbic dopamine system as a target for rapid antidepressant action , 1997, International clinical psychopharmacology.

[7]  R. Beninger,et al.  Depressive Symptoms in Parkinson's Disease: A Comparison With Disabled Control Subjects , 1990, Journal of geriatric psychiatry and neurology.

[8]  P. Finley.  Selective Serotonin Reuptake Inhibitors: Pharmacologic Profiles and Potential Therapeutic Distinctions , 1994, The Annals of pharmacotherapy.

[9]  L. Laitinen.  DESIPRAMINE IN TREATMENT OF PARKINSON'S DISEASE , 1969 .

[10]  R. Hauser,et al.  Sertraline for the treatment of depression in parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[11]  O. Rascol,et al.  Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study , 1998, Movement disorders : official journal of the Movement Disorder Society.

[12]  R. Strang.  Imipramine in Treatment of Parkinsonism: a Double-blind Placebo Study , 1965, British medical journal.

[13]  B. Bergamasco,et al.  Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[14]  W. Gaebel,et al.  Pramipexole, a Dopamine Agonist, in Major Depression: Antidepressant Effects and Tolerability in an Open‐Label Study with Multiple Doses , 1997 .

[15]  J. Cummings,et al.  Depression and Parkinson's disease: a review. , 1992, The American journal of psychiatry.

[16]  J. Cummings,et al.  Depression in Parkinson’s Disease , 1998 .

[17]  Plaut Ea.  Fourier's view on homosexuality. , 1989 .

[18]  A. Markham,et al.  Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. , 1998, Drugs & aging.

[19]  G. Zubenko,et al.  Endoplasmic Reticulum Abnormality in Alzheimer's Disease: Selective Alteration in Platelet NADH-Cytochrome C Reductase Activity , 1989, Journal of geriatric psychiatry and neurology.

[20]  E. N. Steur,et al.  Increase of Parkinson disability after fluoxetine medication. , 1993, Neurology.

[21]  R. Mayeux,et al.  Altered serotonin metabolism in depressed patients with Parkinson's disease , 1984, Neurology.

[22]  H. Mayberg,et al.  Depression in Parkinson's disease: a biochemical and organic viewpoint. , 1995, Advances in neurology.

[23]  C. Tanner,et al.  Bupropion in Parkinson's disease , 1984, Neurology.

[24]  H. C. D. de Vet,et al.  Treatment of depression in Parkinson's disease: a meta-analysis. , 1995, The Journal of neuropsychiatry and clinical neurosciences.

[25]  O. Rascol,et al.  A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. , 1998, Clinical neuropharmacology.

[26]  J. Andersen,et al.  Anti‐depressive treatment in Parkinson's disease A CONTROLLED TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH L‐DOPA , 1980, Acta neurologica Scandinavica.

[27]  Roger Kurlan,et al.  A survey of antidepressant drug use in Parkinson's disease , 1997, Neurology.

[28]  L. Price,et al.  Serotonergic dysfunction in depression associated with Parkinson's disease , 1992, Neurology.

[29]  M. Macculloch,et al.  THE APPLICATION OF ANTICIPATORY AVOIDANCE LEARNING TO THE TREATMENT OF HOMOSEXUALITY. I. THEORY, TECHNIQUE AND PRELIMINARY RESULTS. , 1966, Behaviour research and therapy.

[30]  G. Lenzi,et al.  Dopamine hypersensitivity in migraine: role of the apomorphine test. , 1997, Clinical neuropharmacology.

[31]  E. Tolosa,et al.  Parkinson's disease with depression , 1986, Neurology.

[32]  J. Hesselink.  Serotonin, depression, and PD , 1993, Neurology.

[33]  C. Marsden,et al.  Depression and disability in Parkinson's disease: a follow-up of 132 cases , 1988, Psychological Medicine.

[34]  R. J. Leo,et al.  Movement disorders associated with the serotonin selective reuptake inhibitors. , 1996, The Journal of clinical psychiatry.

[35]  O. Suchowersky,et al.  Interaction of Fluoxetine and Selegiline , 1990, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[36]  J. Friedman,et al.  Does fluoxetine exacerbate Parkinson's disease? , 1992, The Journal of clinical psychiatry.

[37]  H. V. van Praag,et al.  Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side‐effects , 1996, International clinical psychopharmacology.

[38]  F. Graeff,et al.  Role of 5-HT in stress, anxiety, and depression , 1996, Pharmacology Biochemistry and Behavior.

[39]  D. Weiss,et al.  Serotonin Syndrome In Parkinson Disease , 1995, The Journal of the American Board of Family Medicine.

[40]  Lauterbach Ec,et al.  Anxiety disorders in familial parkinsonism. , 1991 .

[41]  M. Jahanshahi,et al.  Depression in Parkinson's disease: a psychosocial viewpoint. , 1995, Advances in neurology.

[42]  S. Toyama,et al.  Is it Safe to Combine a Selective Serotonin Reuptake Inhibitor with Selegiline? , 1994, The Annals of pharmacotherapy.

[43]  Stiebel Vg.  Maintenance electroconvulsive therapy for chronic mentally ill patients: a case series. , 1995, Psychiatric services.

[44]  N. Andreasen.  Improvement of negative symptoms: concepts, definition and assessment , 1997, International clinical psychopharmacology.

[45]  Cheng‐Huai Lin,et al.  The correlation of depression with functional activity in Parkinson’s disease , 1997, Journal of Neurology.

[46]  Matthew A. Menza,et al.  Parkinson's disease and anxiety: Comorbidity with depression , 1993, Biological Psychiatry.

[47]  R. Robinson,et al.  Depression in patients with early versus late onset of Parkinson's disease , 1989, Neurology.

[48]  C. Gottfries.  Scandinavian experience with citalopram in the elderly , 1996, International clinical psychopharmacology.

[49]  J. Cummings,et al.  Risk factors for depression in Parkinson disease. , 1997, Archives of neurology.